Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE I STUDY OF NY-ESO-1 OVERLAPPING PEPTIDES (OLP4) WITH OR WITHOUT IMMUNOADJUVANTS MONTANIDE AND POLY-ICLC VACCINATION OF EPITHELIAL OVARIAN CANCER (EOC), FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER PATIENTS IN SECOND OR THIRD REMISSION.

Next Previous
Trial Profile

A PHASE I STUDY OF NY-ESO-1 OVERLAPPING PEPTIDES (OLP4) WITH OR WITHOUT IMMUNOADJUVANTS MONTANIDE AND POLY-ICLC VACCINATION OF EPITHELIAL OVARIAN CANCER (EOC), FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER PATIENTS IN SECOND OR THIRD REMISSION.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cancer vaccine NY-ESO-1 (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions

Most Recent Events

  • 27 Jul 2018 Biomarkers information updated
  • 17 Apr 2012 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
  • 17 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top